Melanocyte-specific immune response in melanoma and vitiligo: Two faces of the same coin?

Anna Wankowicz-Kalinska; Caroline Le Poole; Rene Van Den Wijngaard; Walter J. Storkus; Pranab K. Das

doi:10.1034/j.1600-0749.2003.00038.x

Melanocyte-specific immune response in melanoma and vitiligo: Two faces of the same coin?

Anna Wankowicz-Kalinska, Caroline Le Poole, Rene Van Den Wijngaard, Walter J. Storkus, Pranab K. Das^*

^*Corresponding author for this work

Dermatology

Research output: Contribution to journal › Article › peer-review

52 Scopus citations

Abstract

The appearance of depigmentation during the course of malignant melanoma has been considered a good prognostic sign. Is it only a side-effect, informative of the immune system's response to the treatment, or does it act as a necessary amplifier of these clinically important anti-tumor responses? The current review will attempt to tackle this question by reviewing the current literature, as well as by posing some novel hypotheses. Understanding the nature of humoral and cellular immune responses directed against normal melanocytes and their malignant counterparts may lead to the design of improved therapeutic strategies relevant to both vitiligo and melanoma.

Original language	English (US)
Pages (from-to)	254-260
Number of pages	7
Journal	Pigment Cell Research
Volume	16
Issue number	3
DOIs	https://doi.org/10.1034/j.1600-0749.2003.00038.x
State	Published - Jun 2003

Keywords

Antibodies
Melanoma
T cells
Vitiligo

ASJC Scopus subject areas

Agronomy and Crop Science
Plant Science
Clinical Biochemistry
Cell Biology
Developmental Biology

Access to Document

10.1034/j.1600-0749.2003.00038.x

Cite this

@article{5653d11b7aa74fc7b89e1e257afbe289,

title = "Melanocyte-specific immune response in melanoma and vitiligo: Two faces of the same coin?",

abstract = "The appearance of depigmentation during the course of malignant melanoma has been considered a good prognostic sign. Is it only a side-effect, informative of the immune system's response to the treatment, or does it act as a necessary amplifier of these clinically important anti-tumor responses? The current review will attempt to tackle this question by reviewing the current literature, as well as by posing some novel hypotheses. Understanding the nature of humoral and cellular immune responses directed against normal melanocytes and their malignant counterparts may lead to the design of improved therapeutic strategies relevant to both vitiligo and melanoma.",

keywords = "Antibodies, Melanoma, T cells, Vitiligo",

author = "Anna Wankowicz-Kalinska and {Le Poole}, Caroline and {Van Den Wijngaard}, Rene and Storkus, {Walter J.} and Das, {Pranab K.}",

year = "2003",

month = jun,

doi = "10.1034/j.1600-0749.2003.00038.x",

language = "English (US)",

volume = "16",

pages = "254--260",

journal = "Pigment Cell Research",

issn = "0893-5785",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Melanocyte-specific immune response in melanoma and vitiligo

T2 - Two faces of the same coin?

AU - Wankowicz-Kalinska, Anna

AU - Le Poole, Caroline

AU - Van Den Wijngaard, Rene

AU - Storkus, Walter J.

AU - Das, Pranab K.

PY - 2003/6

Y1 - 2003/6

N2 - The appearance of depigmentation during the course of malignant melanoma has been considered a good prognostic sign. Is it only a side-effect, informative of the immune system's response to the treatment, or does it act as a necessary amplifier of these clinically important anti-tumor responses? The current review will attempt to tackle this question by reviewing the current literature, as well as by posing some novel hypotheses. Understanding the nature of humoral and cellular immune responses directed against normal melanocytes and their malignant counterparts may lead to the design of improved therapeutic strategies relevant to both vitiligo and melanoma.

AB - The appearance of depigmentation during the course of malignant melanoma has been considered a good prognostic sign. Is it only a side-effect, informative of the immune system's response to the treatment, or does it act as a necessary amplifier of these clinically important anti-tumor responses? The current review will attempt to tackle this question by reviewing the current literature, as well as by posing some novel hypotheses. Understanding the nature of humoral and cellular immune responses directed against normal melanocytes and their malignant counterparts may lead to the design of improved therapeutic strategies relevant to both vitiligo and melanoma.

KW - Antibodies

KW - Melanoma

KW - T cells

KW - Vitiligo

UR - http://www.scopus.com/inward/record.url?scp=0037902609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037902609&partnerID=8YFLogxK

U2 - 10.1034/j.1600-0749.2003.00038.x

DO - 10.1034/j.1600-0749.2003.00038.x

M3 - Article

C2 - 12753398

AN - SCOPUS:0037902609

SN - 0893-5785

VL - 16

SP - 254

EP - 260

JO - Pigment Cell Research

JF - Pigment Cell Research

IS - 3

ER -

Melanocyte-specific immune response in melanoma and vitiligo: Two faces of the same coin?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this